US Stock MarketDetailed Quotes

IKT Inhibikase Therapeutics

Watchlist
  • 2.2000
  • +0.2100+10.55%
Close Mar 11 16:00 ET
  • 2.2000
  • 0.00000.00%
Post 16:05 ET
159.90MMarket Cap-0.71P/E (TTM)

Inhibikase Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
22.20%5.83M
-18.57%5.05M
1.43%4.78M
10.82%20.09M
1.58%4.4M
5.67%4.77M
33.67%6.2M
1.60%4.71M
22.77%18.13M
-14.01%4.33M
Selling and administrative expenses
0.91%1.64M
10.74%1.97M
5.49%2.03M
8.28%6.73M
4.18%1.4M
5.47%1.62M
7.14%1.78M
15.32%1.93M
-4.47%6.22M
-18.68%1.34M
Research and development costs
29.90%4.19M
-32.19%3.08M
-3.60%2.75M
13.16%13.62M
-1.68%3M
8.18%3.23M
52.09%4.54M
-5.40%2.85M
5.95%12.03M
-9.91%3.05M
Other operating expenses
----
----
----
-111.03%-260.5K
100.00%-1
-991.33%-79.57K
-1,676.71%-116.41K
-40.17%-64.52K
96.02%-123.44K
-3,169.86%-63.57K
Operating profit
-22.20%-5.83M
18.57%-5.05M
-1.43%-4.78M
-10.82%-20.09M
-1.58%-4.4M
-5.67%-4.77M
-33.67%-6.2M
-1.60%-4.71M
-22.77%-18.13M
14.01%-4.33M
Net non-operating interest income expense
-71.55%49.41K
-78.58%90.93K
-44.04%132.73K
1,324.94%1.06M
303.47%225.63K
836.97%173.68K
424.44K
4,743,520.00%237.17K
473.70%74.45K
35,493.67%55.92K
Non-operating interest income
-71.55%49.41K
-78.58%90.93K
-44.04%132.73K
1,324.94%1.06M
303.47%225.63K
836.97%173.68K
--424.44K
--237.17K
--74.45K
--55.92K
Other net income (expense)
Income before tax
-25.74%-5.78M
14.16%-4.96M
-3.84%-4.65M
-5.40%-19.03M
2.36%-4.18M
-2.24%-4.6M
-24.53%-5.78M
3.51%-4.48M
-22.10%-18.05M
15.13%-4.28M
Income tax
Net income
-25.74%-5.78M
14.16%-4.96M
-3.84%-4.65M
-5.40%-19.03M
2.36%-4.18M
-2.24%-4.6M
-24.53%-5.78M
3.51%-4.48M
-22.10%-18.05M
15.13%-4.28M
Net income continuous Operations
-25.74%-5.78M
14.16%-4.96M
-3.84%-4.65M
-5.40%-19.03M
2.36%-4.18M
-2.24%-4.6M
-24.53%-5.78M
3.51%-4.48M
-22.10%-18.05M
15.13%-4.28M
Minority interest income
Net income attributable to the parent company
-25.74%-5.78M
14.16%-4.96M
-3.84%-4.65M
-5.40%-19.03M
2.36%-4.18M
-2.24%-4.6M
-24.53%-5.78M
3.51%-4.48M
-22.10%-18.05M
15.13%-4.28M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-25.74%-5.78M
14.16%-4.96M
-3.84%-4.65M
-5.40%-19.03M
2.36%-4.18M
-2.24%-4.6M
-24.53%-5.78M
3.51%-4.48M
-22.10%-18.05M
15.13%-4.28M
Basic earnings per share
13.33%-0.65
29.79%-0.66
25.51%-0.73
16.59%-3.57
-6.86%-1.09
29.25%-0.75
14.55%-0.94
9.26%-0.98
11.93%-4.28
15.00%-1.02
Diluted earnings per share
13.33%-0.65
29.79%-0.66
25.51%-0.73
16.59%-3.57
-6.86%-1.09
29.25%-0.75
14.55%-0.94
9.26%-0.98
11.93%-4.28
15.00%-1.02
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 22.20%5.83M-18.57%5.05M1.43%4.78M10.82%20.09M1.58%4.4M5.67%4.77M33.67%6.2M1.60%4.71M22.77%18.13M-14.01%4.33M
Selling and administrative expenses 0.91%1.64M10.74%1.97M5.49%2.03M8.28%6.73M4.18%1.4M5.47%1.62M7.14%1.78M15.32%1.93M-4.47%6.22M-18.68%1.34M
Research and development costs 29.90%4.19M-32.19%3.08M-3.60%2.75M13.16%13.62M-1.68%3M8.18%3.23M52.09%4.54M-5.40%2.85M5.95%12.03M-9.91%3.05M
Other operating expenses -------------111.03%-260.5K100.00%-1-991.33%-79.57K-1,676.71%-116.41K-40.17%-64.52K96.02%-123.44K-3,169.86%-63.57K
Operating profit -22.20%-5.83M18.57%-5.05M-1.43%-4.78M-10.82%-20.09M-1.58%-4.4M-5.67%-4.77M-33.67%-6.2M-1.60%-4.71M-22.77%-18.13M14.01%-4.33M
Net non-operating interest income expense -71.55%49.41K-78.58%90.93K-44.04%132.73K1,324.94%1.06M303.47%225.63K836.97%173.68K424.44K4,743,520.00%237.17K473.70%74.45K35,493.67%55.92K
Non-operating interest income -71.55%49.41K-78.58%90.93K-44.04%132.73K1,324.94%1.06M303.47%225.63K836.97%173.68K--424.44K--237.17K--74.45K--55.92K
Other net income (expense)
Income before tax -25.74%-5.78M14.16%-4.96M-3.84%-4.65M-5.40%-19.03M2.36%-4.18M-2.24%-4.6M-24.53%-5.78M3.51%-4.48M-22.10%-18.05M15.13%-4.28M
Income tax
Net income -25.74%-5.78M14.16%-4.96M-3.84%-4.65M-5.40%-19.03M2.36%-4.18M-2.24%-4.6M-24.53%-5.78M3.51%-4.48M-22.10%-18.05M15.13%-4.28M
Net income continuous Operations -25.74%-5.78M14.16%-4.96M-3.84%-4.65M-5.40%-19.03M2.36%-4.18M-2.24%-4.6M-24.53%-5.78M3.51%-4.48M-22.10%-18.05M15.13%-4.28M
Minority interest income
Net income attributable to the parent company -25.74%-5.78M14.16%-4.96M-3.84%-4.65M-5.40%-19.03M2.36%-4.18M-2.24%-4.6M-24.53%-5.78M3.51%-4.48M-22.10%-18.05M15.13%-4.28M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -25.74%-5.78M14.16%-4.96M-3.84%-4.65M-5.40%-19.03M2.36%-4.18M-2.24%-4.6M-24.53%-5.78M3.51%-4.48M-22.10%-18.05M15.13%-4.28M
Basic earnings per share 13.33%-0.6529.79%-0.6625.51%-0.7316.59%-3.57-6.86%-1.0929.25%-0.7514.55%-0.949.26%-0.9811.93%-4.2815.00%-1.02
Diluted earnings per share 13.33%-0.6529.79%-0.6625.51%-0.7316.59%-3.57-6.86%-1.0929.25%-0.7514.55%-0.949.26%-0.9811.93%-4.2815.00%-1.02
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------

Trending Stocks

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

No. Symbol Price
Cars.com
CARS
11.810
New Fortress Energy
NFE
9.260
Hutchmed (China)
HCM
15.680
4
Collegium Pharmaceutical
COLL
29.990
5
Dorian LPG
LPG
20.350
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call